Tirofiban - Medicure/Merck & Co
Alternative Names: Aggrastat; L 462; L 700462; MK 0383; MK 383; Tirofiban HCl; Tirofiban hydrochlorideLatest Information Update: 05 Nov 2023
At a glance
- Originator Merck & Co
- Developer 4P Therapeutics; Aspen Pharmacare; Correvio Pharma; Eddingpharm; Medicure; University of Iowa
- Class Anti-ischaemics; Anticoagulants; Antihaemorrhagics; Antithrombotics; Antivirals; Aromatic amino acids; Cardiovascular therapies; Ischaemic heart disorder therapies; Piperidines; Small molecules; Sulfonamides; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Acute coronary syndromes; Arterial thrombosis; Myocardial infarction; Unstable angina pectoris
- Phase I/II Subarachnoid haemorrhage
- No development reported Coronary artery restenosis; COVID 2019 infections
Most Recent Events
- 02 Jan 2023 No development reported - Phase-II for COVID-2019 infections (Combination therapy) in Italy (IV)
- 04 Nov 2021 Efficacy data from the phase II SAVI-PCI trial for Myocardial infarction and Unstable angina pectoris released by Medicure
- 01 Jul 2021 University of Iowa completes a phase I/IIa trial in Subarachnoid haemorrhage (In adults, In the elderly) in USA (IV) (NCT03691727)